BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 38300441)

  • 1. Targeting LTA4H facilitates the reshaping of the immune microenvironment mediated by CCL5 and sensitizes ovarian cancer to Cisplatin.
    Guo Z; Huang J; Huo X; Huang C; Yu X; Sun Y; Li Y; He T; Guo H; Yang J; Xue L
    Sci China Life Sci; 2024 Jun; 67(6):1226-1241. PubMed ID: 38300441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
    Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGFR2-Interferon α Promotes the Infiltration of CD8+ T Cells in Colorectal Cancer by Upregulating the Expression of CCL5.
    Huang L; Gao R; Nan L; Qi J; Yang S; Shao S; Xie J; Pan M; Qiu T; Zhang J
    J Immunother; 2024 Jul-Aug 01; 47(6):195-204. PubMed ID: 38654631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
    Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the immune microenvironment in ovarian cancer patients.
    Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
    Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
    Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
    Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
    Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
    Front Immunol; 2021; 12():799171. PubMed ID: 35095879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib enhanced CD8
    Luo J; Cheng K; Ji X; Gao C; Zhu R; Chen J; Xue W; Huang Q; Xu Q
    Cancer Lett; 2024 Jun; 591():216892. PubMed ID: 38621459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
    Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
    J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting
    Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
    Front Immunol; 2021; 12():738958. PubMed ID: 34721405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.
    Kim S; Han Y; Kim SI; Lee J; Jo H; Wang W; Cho U; Park WY; Rando TA; Dhanasekaran DN; Song YS
    Mol Carcinog; 2021 May; 60(5):297-312. PubMed ID: 33721368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
    Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.
    Fialová A; Partlová S; Sojka L; Hromádková H; Brtnický T; Fučíková J; Kocián P; Rob L; Bartůňková J; Spíšek R
    Int J Cancer; 2013 Mar; 132(5):1070-9. PubMed ID: 22865582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
    Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
    Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.
    Liu J; Wang Y; Yuan S; Wei J; Bai J
    Front Immunol; 2021; 12():751594. PubMed ID: 34745124
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Wang W; Liu S; Lu F; Yang B; Zhuang X; Yin J; Chen G; Sun C
    Oncol Rep; 2023 Jul; 50(1):. PubMed ID: 37264954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
    Jiang L; Fang X; Wang H; Li D; Wang X
    Front Immunol; 2018; 9():2927. PubMed ID: 30619288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.